<table-wrap xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:xlink="http://www.w3.org/1999/xlink" id="table2" position="float"><object-id pub-id-type="doi">10.7554/eLife.46793.025</object-id><label>Table 2.</label><caption><title>Examples of cancer-associated genetic vulnerabilities to G4 ligands.</title></caption><table frame="hsides" rules="groups"><thead><tr><th>Gene category</th><th>Gene name</th><th>Function/pathway Summary</th><th>Cancer <break/>association summary</th><th>References</th></tr></thead><tbody><tr><td rowspan="4">DNA damage repair</td><td>PALB2</td><td>Homologous recombination; binds BRCA2</td><td>Inactivating mutations predispose patients to <break/>myeloid leukaemia, Wilm&#8217;s tumour <break/>and Fanconi anaemia.</td><td><xref ref-type="bibr" rid="bib55">Harrigan et al., 2018</xref>; <break/><xref ref-type="bibr" rid="bib91">Nepomuceno et al., 2017</xref> <break/> <break/> <break/> <break/><break/></td></tr><tr><td>&#8195;BAP1</td><td>Homologous recombination; binds BRCA1, deubiquitinase for Histone 2A and tumour suppressor HCFC-1</td><td>Inactivating mutations foundin uveal melanoma and mesotheliomas.</td><td><xref ref-type="bibr" rid="bib55">Harrigan et al., 2018</xref>; <xref ref-type="bibr" rid="bib21">Carbone et al., 2013</xref></td></tr><tr><td>&#8195;USP1</td><td>Fanconi anaemia and translesion synthesis DDR; deubiquitinase required for FANCD2, FANCI and PCNA localisation to sites of DNA <break/>damage</td><td>USP1 mRNA over-expressed in melanoma, gastric, cervical and NSCLC; under-expressed in leukaemia and lymphoma.</td><td><xref ref-type="bibr" rid="bib55">Harrigan et al., 2018</xref>; <break/><xref ref-type="bibr" rid="bib92">Nijman et al., 2005</xref>; <break/><xref ref-type="bibr" rid="bib58">Huang et al., 2006</xref>; <break/><xref ref-type="bibr" rid="bib46">Garc&#237;a-Santisteban et al., 2013</xref></td></tr><tr><td>&#8195;TOP1</td><td>Relieves torsional stress during DNA replication; suppresses genomic instability at actively transcribed exogenous G4-forming sequences</td><td>Common cancer target, to <break/>induces DNA damage following pharmacological inhibition, lethal to cells.</td><td><xref ref-type="bibr" rid="bib131">Yadav et al., 2014</xref>; <break/><xref ref-type="bibr" rid="bib121">Wang, 2002</xref></td></tr><tr><td>Helicase activity</td><td>RECQL4 RTEL1</td><td>Previously identified G4-helicases</td><td>RECQL4 (Rothmund-Thomsun syndrome) and RTEL1 (Hoyeraal-Hreidarsson Syndrome), deficiencies impart increased risks of cancer cancer, autoimmunity and premature ageing.</td><td><xref ref-type="bibr" rid="bib17">Brosh, 2013</xref></td></tr><tr><td rowspan="3">Chromatin remodellers</td><td>ANKRD11</td><td>Transcription factor; Recruits histone deacetylases</td><td>Tumour suppressor epigenetically silenced in breast cancers.</td><td><xref ref-type="bibr" rid="bib73">Lim et al., 2012</xref> <break/><xref ref-type="bibr" rid="bib90">Neilsen et al., 2008</xref> <break/><xref ref-type="bibr" rid="bib94">Noll et al., 2012</xref></td></tr><tr><td>MLL4</td><td>H3K4 lysine methyl transferase</td><td>Frequently inactivated in several cancers.</td><td><xref ref-type="bibr" rid="bib44">Froimchuk et al., 2017</xref><xref ref-type="bibr" rid="bib64">Kadoch et al., 2013</xref>; <break/><xref ref-type="bibr" rid="bib98">Rao and Dou, 2015</xref></td></tr><tr><td>SMARCA4 SMARCB1 SMARCE1</td><td>SWI/SNF ATP-dependent chromatin remodellers</td><td>Mutated in 20% of human cancers; doxorubicin resistant triple-negative breast cancer is associated with loss of SMARCB1, SMARCA4, or KEAP1 (a BRCA1 interactor).</td><td><xref ref-type="bibr" rid="bib64">Kadoch et al., 2013</xref>; <break/><xref ref-type="bibr" rid="bib108">Shain and Pollack, 2013</xref></td></tr><tr><td rowspan="3">Ubiquitin</td><td>USP37</td><td>Deubiquitinating enzyme which stabilises MYC</td><td>Upregulated in lung cancer.</td><td><xref ref-type="bibr" rid="bib95">Pan et al., 2015</xref></td></tr><tr><td>NEDD4L</td><td>E3 ubiquitin ligase</td><td>Expression correlates with poor patient outcome in hepatocellular and gastric carcinomas.</td><td><xref ref-type="bibr" rid="bib135">Zhao et al., 2018</xref>; <break/><xref ref-type="bibr" rid="bib45">Gao et al., 2012</xref></td></tr><tr><td>RNF20</td><td>E3 ubiquitin ligase; chromatin remodelling and DDR</td><td>Tumour supressor down-regulated in several cancers. Deletion is main contributor to chromosomal instability in colorectal cancer.</td><td><xref ref-type="bibr" rid="bib87">Moyal et al., 2011</xref>; <break/><xref ref-type="bibr" rid="bib110">Shema et al., 2008</xref>; <break/><xref ref-type="bibr" rid="bib8">Barber et al., 2008</xref></td></tr><tr><td>Splicing</td><td>FUS</td><td>Splicing component and known G4-interactor</td><td>Over-expressed in colon, breast and liposarcoma cancers, respectively.</td><td><xref ref-type="bibr" rid="bib31">Crozat et al., 1993</xref>; <break/><xref ref-type="bibr" rid="bib39">Dvinge et al., 2016</xref>; <xref ref-type="bibr" rid="bib116">Takahama et al., 2013</xref></td></tr></tbody></table></table-wrap>